Neuropathix, Inc. - NPTX STOCK NEWS

Neuropathix (OTCQB:NPTX) announced promising preclinical data demonstrating that its cannabinoid-derived candidate KLS-13019 effectively prevents and reverses chemotherapy-induced peripheral neuropathy (CIPN), outperforming cannabidiol (CBD). Conducted at Temple University, the studies showed KLS-13019 could reverse CIPN-related pain while CBD could not. This discovery, supported by a $2.97 million NIH HEAL grant, positions KLS-13019 for potential IND filing and underscores its low risk for dependency. The global neuropathic pain market is projected to grow from $6.3 billion in 2019 to $9.8 billion by 2027.

Neuropathix (OTCQB:NPTX) announced milestones in its recent shareholder letter, highlighting growth in its investor base and securing a $2.97 million NIH grant for its lead drug candidate KLS-13019, aimed at treating chemotherapy-induced peripheral neuropathy (CIPN). The grant, awarded based on a peer-reviewed priority impact score of 20, underscores KLS-13019's potential as a non-addictive alternative to opioids. The company is preparing for an IND filing, with significant steps planned for 2022 and early 2023, enhancing its clinical development and research support.

Neuropathix (OTCQB:NPTX) has appointed Dr. Daniele Piomelli, a leading expert in pharmacology and neuroscience, to its Scientific Advisory Board. Dr. Piomelli's extensive background includes over 415 peer-reviewed articles and multiple patents, positioning him to significantly contribute to the development of KLS-13019, Neuropathix's lead compound aimed at treating inflammation and neuropathic pain. Dr. Piomelli recognizes the urgent need for non-opioid pain alternatives, aligning with Neuropathix's mission to address chronic pain without the downsides of opioid medications.

Neuropathix has secured Indian Patent IN201617027528 for its novel therapeutic compounds, expanding its global patent portfolio for the treatment of debilitating neurological conditions. The Company's lead candidate, KLS-13019, aims to address chemotherapy-induced peripheral neuropathy, a condition lacking FDA-approved treatments. Neuropathix's intellectual property now spans significant pharmaceutical markets, enhancing its competitive position. Additionally, the Company received a $2.97 million grant from the NIH for continued development of KLS-13019, bolstering its financial resources for research.

Neuropathix, Inc. (OTCQB:NPTX) has partnered with Purisys LLC for the optimization and scaling of its lead drug candidate, KLS-13019, aimed at treating chemotherapy-induced peripheral neuropathy (CIPN). The collaboration enhances the production of synthetic APIs, paving the way for upcoming animal toxicity studies and future human clinical trials. Neuropathix recently received a $2.97 million grant from the NIH for the development of KLS-13019, underscoring its commitment to addressing significant unmet medical needs.

Neuropathix has received a $2.97 million Phase 2 STTR Study Grant from the NIH for its non-opioid compound, KLS-13019, targeting Chemotherapy-Induced Peripheral Neuropathy (CIPN). This grant, part of the HEAL Initiative, will fund research over three years, focusing on preclinical studies and preparing for FDA human clinical trials. The compound has shown promise in animal studies for reversing chemotherapy-related pain. The company aims to address the opioid crisis by developing alternative pain management solutions.

Neuropathix, Inc. (OTCQB:NPTX) announced the formation of a new wholly owned subsidiary, Dermique Incorporated, to commercialize its cosmeceutical assets, including the lead anti-inflammatory compound LEA™ (Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine). The strategy aims to separate over-the-counter (OTC) products from its longer-term pharmaceutical pipeline, enhancing marketing flexibility and attracting investments. Preclinical studies show LEA™ outperforms CBD in targeting inflammation and related disorders. The global cosmeceutical market is projected to grow significantly, indicating strong potential for Dermique's offerings.

Neuropathix (OTCQB:NPTX) has appointed Dr. Michael Ropacki to its Scientific Advisory Board. Dr. Ropacki, a recognized leader in CNS research with over 20 years of experience, has been tasked with advising on the clinical development of Neuropathix's lead drug candidate KLS-13019 and its topical API, LEA. His background includes significant roles at Oryzon and Johnson & Johnson. This strategic appointment aims to enhance the company’s efforts in pain management and address the opioid crisis, with Dr. Ropacki expressing enthusiasm for contributing to Neuropathix's mission.

Neuropathix, Inc. (OTCQB:NPTX) announced the publication of its global Patent Cooperation Treaty (PCT) Patent No. WO/2021/097351, focusing on LEA™, a compound aimed at treating radiation dermatitis and other skin disorders. LEA™ demonstrated superior anti-inflammatory properties compared to cannabidiol in preclinical tests. The company plans to launch two branded products containing LEA™ in 2022, capitalizing on the growing global sun care market, projected to reach $24.9 billion by 2024. Neuropathix continues to develop therapeutics for unmet medical needs.